← ANALYST RATINGS · TIPRANKS
Pharvaris (PHVS): analyst forecast and price target
Analyst consensus
Strong Buy10 Buy0 Hold0 Sell
Ratings of 10 analysts in the last 3 months · top analysts only12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $63.00, the highest $79.00, the lowest $44.00. The average is +127.1% from the last price of $27.74.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $31.00 → $28.00−9.7% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $29.00 → $27.00−6.9% | Hold | −2.7% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $31.00 → $29.00−6.5% | Hold | +4.5% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $30.00 → $28.00−6.7% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $31.00 → $29.00−6.5% | Hold | +4.5% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $31.00 → $28.00−9.7% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $65.00 | Buy | +134.3% | Reiterated | 15.10.26on TipRanks 07:50 | −1.6%next day −5.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $32.00 → $31.00−3.1% | Hold | +11.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $30.00 → $29.00−3.3% | Hold | +4.5% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $32.00 → $31.00−3.1% | Hold | +11.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $31.00 → $30.00−3.2% | Hold | +8.1% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $32.00 → $31.00−3.1% | Hold | +11.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $32.00 → $31.00−3.1% | Hold | +11.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| Maxwell Skor★★★★★★★★★★#486 · hits 74% · avg +28.0% | Morgan Stanley | $62.00 | Buy | +123.5% | Assigned | 12.10.26on TipRanks 08:20 | −0.6%next day −2.8% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $33.00 → $32.00−3.0% | Hold | +15.4% | Reiterated | 11.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $31.00 → $30.00−3.2% | Hold | +8.1% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $60.00 | Buy | +116.3% | Reiterated | 06.10.26on TipRanks 06:25 | +1.5%next day +2.0% · 5 days −3.4% | ↗ |
| Maxwell Skor★★★★★★★★★★#486 · hits 74% · avg +28.0% | Morgan Stanley | $62.00 | Buy | +123.5% | Assigned | 05.10.26on TipRanks 08:35 | −2.9%next day +1.5% · 5 days +0.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $32.00 | Hold | +15.4% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $31.00 | Hold | +11.8% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $32.00 | Hold | +15.4% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $31.00 | Hold | +11.8% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $33.00 | Hold | +19.0% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $32.00 | Hold | +15.4% | Reiterated | 05.10.26on TipRanks 05:05 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $60.00 | Buy | +116.3% | Reiterated | 21.09.26on TipRanks 13:55 | −2.5%next day −2.3% · 5 days −10.4% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $50.00 → $65.00+30.0% | Buy | +134.3% | Assigned | 10.09.26on TipRanks Sep 9 08:50 | +0.2%next day 0.0% · 5 days +0.6% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $40.00 → $44.00+10.0% | Buy | +58.6% | Reiterated | 09.09.26on TipRanks Sep 10 07:10 | +0.2%next day 0.0% · 5 days +0.6% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $42.00 → $50.00+19.0% | Buy | +80.2% | Reiterated | 09.09.26on TipRanks 08:50 | +0.2%next day 0.0% · 5 days +0.6% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $46.00 → $65.00+41.3% | Buy | +134.3% | Reiterated | 09.09.26on TipRanks 08:50 | +0.2%next day 0.0% · 5 days +0.6% | ↗ |
| Nevin Varghese★★★★★★★★★★#6891 · hits 100% · avg +19.2% | RBC Capital | $52.00 → $62.00+19.2% | Buy | +123.5% | Reiterated | 09.09.26on TipRanks 07:30 | +0.2%next day 0.0% · 5 days +0.6% | ↗ |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $52.00 → $65.00+25.0% | Buy | +134.3% | Reiterated | 09.09.26on TipRanks 06:50 | +0.2%next day 0.0% · 5 days +0.6% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $55.00 → $65.00+18.2% | Buy | +134.3% | Reiterated | 09.09.26on TipRanks 06:15 | +0.2%next day 0.0% · 5 days +0.6% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $75.00 → $79.00+5.3% | Buy | +184.8% | Reiterated | 09.09.26on TipRanks 06:00 | +0.2%next day 0.0% · 5 days +0.6% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $38.00 → $44.00+15.8% | Hold | +58.6% | Reiterated | 08.09.26on TipRanks 22:25 | +0.2%next day 0.0% · 5 days +0.6% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $50.00 → $75.00+50.0% | Buy | +170.4% | Reiterated | 08.09.26on TipRanks 14:50 | +7.9%next day +0.2% · 5 days +1.7% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $42.00 | Buy | +51.4% | Initiated | 08.04.26on TipRanks 16:45 | −2.4%next day −1.6% · 5 days +3.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Pharvaris
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $61.33 at a price of $31.19 (+96.6%); now: $61.33 at $27.74 (+121.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 10 | 7 | 5 | 15 | 18 |
| Buy | 5 | 8 | 6 | 11 | 10 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.81 (from $-0.90 to $-0.75). Last quarter: $-0.79.
Best top-analyst consensus in the sector · Healthcare
About Pharvaris
- CEO: Berndt Modig
- Employees: 148
- Grafenauweg 8, Zug, ZH, 6300, CH
- pharvaris.com
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Data from the stock’s TipRanks forecast page, read 40 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗